Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.54 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 6/20 | 0.38 |
| ▸ | SCN2A | Q99250 | 5/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679441 | 0.80 | GRM5 (0.50) | GRM5CTSAS1PR3CNR1GAA | |
| SCHEMBL15921102 | 0.80 | GRM5 (0.50) | GRM5CTSAS1PR3CNR1HPGD | |
| SCHEMBL13097165 | 0.78 | GRM5 (0.54) | GRM5CNR1RAB9AGAAHPGD | |
| SCHEMBL164543 | 0.78 | CNR1 (0.42) | GRM5CNR1RAB9AGAAHPGD | |
| SCHEMBL26986930 | 0.78 | CNR1 (0.42) | GRM5CNR1RAB9AGAAHPGD | |
| SCHEMBL30354632 | 0.78 | GRM5 (0.46) | GRM5CTSAS1PR3RAB9AHPGD | |
| SCHEMBL12091007 | 0.78 | GRM5 (0.46) | GRM5CTSAS1PR3RAB9AHPGD | |
| SCHEMBL27858703 | 0.77 | GRM5 (0.49) | GRM5CTSAS1PR3HPGDSCN10A | |
| SCHEMBL1134502 | 0.77 | MRGPRX4 (0.49) | GRM5CTSAS1PR3RAB9ACDK2 | |
| SCHEMBL22792229 | 0.77 | CTSA (0.48) | GRM5CTSACNR1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347588-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-C]PYRIDINE DERIVATIVES | JANSSEN Pharmaceutica NV (BE) | 2024-04-10 | — | — | EP | disclosed |
| CN-117396476-A | Substituted phenyl-1H-pyrrolo [2,3-c ] pyridine derivatives | 詹森药业有限公司 | 2024-01-12 | — | — | CN | disclosed |
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-10 | — | — | US | disclosed |
| WO-2022253167-A1 | SUBSTITUTED PHENYL-1H-PYRROLO [2, 3-c] PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2022-12-08 | — | — | WO | disclosed |
| US-9682995-B2 | Amino-substituted isothiazoles | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-20 | — | — | US | disclosed |
| EP-2951174-B1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma AG (DE) | 2017-04-26 | — | — | EP | disclosed |
| US-20150368260-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-12-24 | — | — | US | disclosed |
| EP-2951174-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | Bayer Pharma Aktiengesellschaft (DE) | 2015-12-09 | — | — | EP | disclosed |
| WO-2014118186-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-08-07 | — | — | WO | disclosed |
| EP-2152700-B1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-8293769-B2 | CSF-1R inhibitors, compositions, and methods of use | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| EP-2152700-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Novartis Ag (CH) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008144062-A1 | CSF-1R INHIBITORS, COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250096-A1 | SUBSTITUTED PHENYL-1H-PYRROLO[2,3-c] PYRIDINE DERIVATIVES | MLLT1, BMI1, MEN1 | GRM5 2777/4885CTSA 2657/4885S1PR3 2756/4885 |
| US-20150368260-A1 | AMINO-SUBSTITUTED ISOTHIAZOLES | BUB1B, BUB1, CCNB1 | GRM5 2893/4885CTSA 2637/4885S1PR3 2161/4885 |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | GRM5 1825/4885CTSA 105/4885S1PR3 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.